Articles tagged with Prostate Cancer
A recent study found that nearly a third of college students are overweight, while six percent are pre-diabetic. The findings suggest that early screening is crucial for preventing long-term health problems. Researchers also discovered that polyunsaturated fat intake may be linked to slower growth of prostate cancer.
A gene mutation that protects against malaria has been found to increase the risk of aggressive prostate cancer in African-American men. Researchers discovered that mice with this mutation developed larger, more aggressive tumors due to increased angiogenic chemokine production.
A new study has found that radiation therapy for prostate cancer increases the risk of developing rectal cancer by approximately 70%. The research team recommends monitoring men who have received radiation for prostate cancer starting five years after treatment.
A study published by the American Gastroenterological Association finds that radiation therapy for prostate cancer nearly doubles the risk of developing rectal cancer. Researchers recommend aggressive monitoring for men treated with radiation starting five years after treatment.
Researchers found that sociocultural and racial factors independently predicted treatment patterns in early-stage prostate cancer. Married men were more likely to receive curative treatment than unmarried men, regardless of ethnicity.
Researchers at Emory University Health Sciences Center have identified a new tumor suppressor gene, ATBF1, which inhibits cell proliferation. This finding suggests that ATBF1 may play a role in the development of prostate cancer and potentially other types of cancers.
A study found that carriers of a genetic variant associated with low antioxidant levels in the blood have a significantly increased risk of developing aggressive prostate cancer. The research highlights the potential role of antioxidants such as selenium and vitamin E in preventing prostate cancer.
A massive study is examining prostate cancer screening practices to determine their impact on death rates. The study follows 75,000 men, half of whom are screened and half receive conventional care, allowing researchers to compare survival rates.
Researchers created tumor-specific immune cells that were insensitive to TGF-beta, a powerful substance that helps cancer cells evade the immune system. These cells were able to infiltrate and destroy tumors effectively, while preventing autoimmune disease, offering new hope for treating advanced prostate cancer.
A new study found that nearly two-thirds of men are up-to-date with prostate cancer screening, but only 47.6% have had a recent colon cancer screening. The researchers suggest using prostate cancer screenings as an opportunity to encourage men to get screened for colon cancer, which is projected to affect over 70,000 men this year.
Researchers found celecoxib reduces prostate cancer cell growth and proliferation by targeting both COX-2 and cyclin D1. In animal models, celecoxib also reduced tumor mass and blood vessel density, suggesting a potential new therapeutic approach for treating prostate cancer.
Research found that hormone therapy for prostate cancer can lead to temporary declines in visual memory and recognition speed. However, cognitive function appears to be well preserved despite these changes.
The study found finasteride reduced the incidence of prostate cancer by 24.8% compared to a placebo, potentially saving thousands of lives over ten years. Despite an increase in high-grade tumors, the analysis shows that this benefit outweighs the potential drawbacks.
A new urinary marker, thymosin ß15, has been identified as a potential more accurate screening test for prostate cancer. When combined with PSA testing, it detects prostate cancer more often with fewer false-positives.
Researchers identified an inherited gene variant associated with a 50% increased risk of prostate cancer, revealing a new pathway for the disease's development. The study found that individuals carrying this variant face a higher risk of developing prostate cancer.
A study found that obesity can make prostate cancer screenings less accurate, leading to delayed diagnoses and poorer treatment outcomes. The research suggests that physicians should consider adjusting PSA values when screening for prostate cancer in overweight or obese men.
A new study found that adding more types to the current HPV DNA test would detect relatively few additional cases of cervical cancer but lead to thousands of unnecessary exams for women without cancer. Meanwhile, esophageal adenocarcinoma has increased by sixfold over the last 25 years, with no clear explanation for the rise.
Researchers found mitochondrial DNA mutations in 12% of prostate cancer samples and 7.8% of general population controls, with increased tumor growth and oxygen radical production in mutant cells. These findings suggest a causal link between mtDNA mutations and prostate cancer development, particularly in African men.
A study published in Cancer Research found that BPA exposure can lead to increased cancer cell growth in prostate cancer cells with mutated androgen receptors. This discovery has implications for men diagnosed with BPA-susceptible mutations, who may be at higher risk of cancer progression.
A Purdue University scientist has discovered that gamma-tocopherol, a form of vitamin E found in plant seeds, can inhibit the growth of prostate and lung cancer cells without harming healthy cells. The study suggests that supplementing with mixed forms of vitamin E may enhance its anticancer effects.
Researchers found that green tea polyphenols reduce levels of insulin-like growth factor-1 (IGF-1) in prostate tumor cells, leading to decreased cell survival and tumor growth. The study also showed that GTP inhibited the expression of proteins associated with metastasis and reduced vascular endothelial growth factor (VEGF) levels.
Researchers discovered that the HER2/ERBB3 pathway regulates androgen receptor function, contradicting previous beliefs about EGFR's role. This finding may explain limited success of Gefitinib, an EGFR inhibitor, in treating hormone-refractory prostate cancer.
Researchers are exploring the potential of tomato oil to reverse or delay progression of high-grade prostatic intraepithelial neoplasia (HGPIN), a precursor to prostate cancer. The study, led by Dr. Peter Gann, aims to clarify lycopene's mechanisms in the prostate and determine its chemopreventive potential.
A randomised clinical trial found that post-operative radiotherapy significantly improved biological and clinical progression-free survival in men with high-risk prostate cancer. The study showed a clear benefit in terms of biological progression-free survival for men who received radiotherapy treatment in addition to surgery.
A multi-center, double-blind study found that patients taking toremifene 20 mg had a lower cumulative incidence of cancer after 12 months, with a 48% reduction compared to placebo. High-grade prostatic intraepithelial neoplasia (PIN) is a precursor to prostate cancer.
A recent study published by the American Association for Cancer Research found that men with high-grade prostate intraepithelial neoplasia (PIN) are at a higher risk of developing invasive prostate cancer. Within one year, men in the placebo group had a 31.4% risk of being diagnosed with prostate cancer.
African-American men reported significantly higher sexual and urinary function five years after prostatectomy compared to non-Latino white men. However, they also experienced slightly more bother from changes in their function.
Researchers found that younger men and those with increased disease recurrence risk experience more frequent PSA bounces, but without additional treatment, their survival rates are comparable to those without a bounce. The large-scale study provides evidence that a PSA bounce may not automatically dictate hormone therapy.
Researchers found that docetaxel administered every three weeks significantly improved survival, pain relief, and quality of life for patients with advanced hormone-refractory prostate cancer. The treatment increased life expectancy by an average of three months.
Researchers examined the effect of treatment delay on patients treated with external-beam radiation for prostate cancer. The study found that a delay within certain limits does not alter ultimate clinical outcome, but using hormone therapy during this time should be avoided in men with favorable risk factors.
Researchers at Mount Sinai present groundbreaking studies on prostate and breast cancer treatments, identifying genetic predictors for adverse side effects and developing tailored radiotherapy regimens. The studies aim to improve clinical trials and patient outcomes for these devastating diseases.
A recent study published by Fox Chase Cancer Center found that patients who used nonsteroidal anti-inflammatory drugs (NSAIDs) regularly before their diagnosis and treatment had improved overall survival rates. The research involved 1,206 men with localized prostate cancer and compared the outcomes of those who used NSAIDs regularly to...
A study found that black men aged 65+ were half as likely to be tested for prostate cancer as white men, highlighting racial disparities in healthcare access. Low screening rates among African American men may contribute to higher prostate cancer mortality rates.
A study of over 67,000 men found blacks are 35% less likely than whites to undergo PSA testing, with disparities in healthcare access and education levels potentially contributing factors
A study found that even healthy subjects experience declines in sexual function over five years, but patients treated for prostate cancer show much greater decline with significant impact on urinary function. Men undergoing radical prostatectomy are particularly affected.
Men who consumed four or more glasses of red wine per week reduced their risk of prostate cancer by 50 percent, while white wine showed no significant effect. The study suggests resveratrol, an antioxidant in red grapes, may be responsible for this benefit.
A new study found that prostate cancer treatment can significantly impact men's quality of life, with both radical prostatectomy and radiotherapy causing declines in sexual function, urinary incontinence, and bowel issues. The study, which followed over 1,100 men with clinically localized prostate cancer, suggests that the treatments d...
Researchers found that Hedgehog activity in localized prostate tumors is significantly lower than in metastatic cancers. Blocking the Hedgehog signal with cyclopamine slowed tumor growth and even reversed aggressive cancer progression in mice experiments.
Researchers found that Hedgehog signaling is greatly activated in prostate cancers, distinguishing them from benign ones. The study's findings suggest that targeting the Hedgehog pathway may lead to new treatments for human disease.
A study by Thomas Stamey and colleagues found that the correlation between PSA levels and prostate cancer severity has decreased over time, making the test less useful for early detection. Instead, they recommend a yearly digital rectal exam for men over 50.
A recent study found that popular magazines rarely provide in-depth information on prostate and colon cancer screening. Key points such as risk factors, early screening benefits, and potential harms are often missing from magazine articles. This lack of information may contribute to the public's misperception about cancer risks.
Researchers found that mice engineered to lose a single copy of the Rb gene in their prostate develop a precancerous condition analogous to human prostate cancer. This suggests that loss of Rb could be the initial spark for prostate cancer development.
A molecule called hepsin has been found to promote the deadly progression of prostate cancer by disrupting tissue organization. This discovery may lead to the development of new therapeutics designed to decrease the spread of prostate cancer.
A large family-based study identified specific genes associated with increased prostate cancer susceptibility, highlighting the potential for early detection and targeted surveillance. The study's findings also revealed that prostate cancers in genetically predisposed individuals tend to be more aggressive and fatal.
A new study has identified five chromosomal regions that are likely to harbor prostate cancer susceptibility genes. The study found evidence of a gene on the long arm of chromosome 17 and four other regions that might hold susceptibility genes. Additionally, researchers have discovered that men who carry a specific mutation in the MIC-...
Using combination therapies that include 6 months of androgen suppression therapy (AST) alongside radiation therapy (RT) improves survival rates for patients with locally advanced prostate cancer. The study found significantly higher survival rates, lower prostate cancer-specific mortality, and a reduced need for salvage AST in the com...
Researchers have identified strong evidence for a prostate cancer gene on chromosome 17, which is also known to harbor the breast cancer gene BRCA1. A separate study found that a variant of the MIC-1 gene, involved in inflammation, is associated with a decreased risk for prostate cancer.
Researchers found that prostate cancer cells shed immunostimulatory molecules, allowing them to evade the immune system's natural killer cell defense. Soluble MIC levels in serum correlated with high-grade and invasive tumor status, suggesting a potential biomarker for disease progression.
Researchers have discovered a new gene, EphB2, that plays a critical role in regulating tissue organization and maintaining normal cell behavior. The study found that this gene is inactivated in prostate cancer cells, leading to disorganization and tumor growth.
Thomas Jefferson University is developing a clinical trial using a bone-targeted agent to treat microscopic bony metastasis in high-risk prostate cancer patients. The trial aims to improve death rates from prostate cancer by combining hormones and radiation with the targeted agent, Quadramet.
Researchers found DNA and proteins from BK virus in prostate tissue with abnormal cell changes, a precursor stage of prostate cancer. The virus may induce uncontrolled cell growth, leading to cancer.
A new study by Mount Sinai School of Medicine researchers found that combining three therapeutic modalities increases the percentage of high-risk patients who are free from recurrence after five years. A three-pronged approach that included brachytherapy, external beam radiation therapy and hormonal therapy produced an 86 percent rate ...
Researchers identified 671 genes with altered expression in prostate cancer tissue, revealing a high degree of similarity between benign adjacent tissue and cancerous tissue. The study found that genetic alterations occur throughout the gland, even in seemingly benign areas, providing new insights into prostate cancer progression.
A recent study found a significant correlation between active Stat5 protein and high-grade prostate cancer. The research suggests that blocking the signals that turn on Stat5 may lead to effective treatment strategies for advanced prostate cancer.
Two projects aim to study angiogenesis and anti-angiogenic therapy, as well as the interaction between hormones and growth factors in prostate tumor growth. The ultimate goal is to develop new treatment strategies that suppress metastases by prolonging dormant states.
A study published in NEJM found that rapid rise in PSA levels prior to diagnosis is a stronger indicator of prostate cancer death than the actual PSA level. Early and annual testing are recommended for men with high PSA velocity to detect potential aggressiveness of cancers.
Researchers found that bicalutamide treatment resulted in increased bone mineral density, reduced body fat, and fewer side effects compared to leuprolide. This study suggests a single-drug treatment plan using bicalutamide may be an attractive alternative for men with non-metastatic prostate cancer.
A new study suggests that early hormone therapy can increase survival time by up to 14 years for men with aggressive prostate cancer, compared to those who delay treatment. Prostate cancer affects over 220,000 men annually in the US, with approximately 30,000 dying from the disease each year.
Researchers found that Cox-2 inhibitors slowed disease progression in men with recurrent prostate cancer by inhibiting tumor growth and increasing programmed cell death. The study showed significant results in 22 of 24 patients, with a 92% reduction in PSA levels after three months.
A study of 223 patients with early-stage, initially untreated prostate cancer found that disease progression increased significantly after 15 years of follow-up. After 10-15 years, most cancers had an indolent course, but progression rates decreased over time.